NICE has recommended a pioneering blood cancer therapy tisagenlecleucel

NICE recommends blood cancer therapy tisagenlecleucel

NICE has recommended a pioneering blood cancer therapy tisagenlecleucel, this is a CART-cell therapy for young people with blood cancer.  Young people with relapsed or...
A £500,000 grant could help to advance development of a new antibiotic.

£500k grant could lead to new class of antibiotic

A new antibiotic hailed as the 'last line of defence' in the battle against drug-resistant superbugs such as MSRA and VRE is taking the...
Man taking stars from the EU flag to demonstrate the impact of brexit

Pharmaceutical industry’s response to Brexit ‘draft agreement’

The Association of the British Pharmaceutical Industry (ABPI) has welcomed the announcement of the Withdrawal Agreement and political declaration on the UK’s future relationship...
heart failure drug Entresto

Novartis’ heart failure drug Entresto supported by new study

New Novartis study supports heart failure drug Entresto as foundational HFrEF therapy and in-hospital initiation in appropriate stabilised heart failure patients.  Novartis has announced the...
syringe and tables showing advances in diabetes medicine

Advances in diabetes medicine and unmet needs

Advances in diabetes medicine, such as anti-diabetic oral medications, incretin therapies, and novel insulin formulations have been made over the past century, but many...
First single inhaler triple therapy to be specifically indicated for COPD patients not adequately treated with dual bronchodilation.

Once-daily Trelegy Ellipta gets expanded COPD indication in EU

GlaxoSmithKline and Innoviva, Inc have announced that the European Commission has authorised an expanded label for COPD treatment once-daily Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol ‘FF/UMEC/VI’),...
EUSA Pharma's targeted cancer immunotherapy, QARZIBA®▼ (dinutuximab beta) has been approved across Scotland for children with high-risk neuroblastoma.

Targeted cancer immunotherapy QARZIBA®▼ approved in Scotland

EUSA Pharma's targeted cancer immunotherapy, QARZIBA®▼ (dinutuximab beta) has been approved across Scotland for children with high-risk neuroblastoma. EUSA welcomed the decision by the Scottish...
Microscope showing virus to depict study that finds poxvirus tricks cells

Poxvirus tricks cells into moving to spread infection

A new study led by scientists at the MRC Laboratory for Molecular Cell Biology at UCL has found that a poxvirus tricks cells into...
Image of a heart and medical equipment to show using data to reduce the risk of stroke

Positive results for AZ’s Farxiga in DECLARE-TIMI 58 trial

AstraZeneca has announced positive full results from the DECLARE-TIMI 58 cardiovascular (CV) outcomes trial (CVOT) for Farxiga (dapagliflozin). The data were presented as a late-breaking...
A £500,000 grant could help to advance development of a new antibiotic.

Complacency on infectious diseases risking longevity gains

Experts in health and infectious diseases have gathered at the Science Museum, London, to explore what should be done to ensure that the world...

Latest articles

Sugar supplement mannose has been shown to slow tumour growth in mice.

Sugar supplement slows tumour growth

Mannose sugar, a nutritional supplement, has been shown to both slow tumour growth and enhance the effects of chemotherapy in mice with multiple types...
Dr Ian Hudson is to step down from the helm of the MHRA in September 2019.

Breaking news: MHRA CEO to step down

Dr Ian Hudson, Chief Executive of the Medicines and Healthcare products Regulatory Agency (MHRA), has announced he is to leave his role in September...
clinical use of dimethyl fumarate for plaque psoriasis

Expert consensus on dimethyl fumarate for plaque psoriasis

The first European expert consensus on clinical use of dimethyl fumarate for plaque psoriasis has been published.  The Journal of the European Academy of Dermatology...